Many primary care professionals manage injection or infusion therapies in patients with diabetes. Few published guidelines have been available to help such professionals and their patients manage these therapies. Herein, we present new, practical, and comprehensive recommendations for diabetes injections and infusions. These recommendations were informed by a large international survey of current practice and were written and vetted by 183 diabetes experts from 54 countries at the Forum for Injection Technique and Therapy: Expert Recommendations (FITTER) workshop held in Rome, Italy, in 2015. Recommendations are organized around the themes of anatomy, physiology, pathology, psychology, and technology. Key among the recommendations are that the shortest needles (currently the 4-mm pen and 6-mm syringe needles) are safe, effective, and less painful and should be the first-line choice in all patient categories; intramuscular injections should be avoided, especially with long-acting insulins, because severe hypoglycemia may result; lipohypertrophy is a frequent complication of therapy that distorts insulin absorption, and, therefore, injections and infusions should not be given into these lesions and correct site rotation will help prevent them; effective long-term therapy with insulin is critically dependent on addressing psychological hurdles upstream, even before insulin has been started; inappropriate disposal of used sharps poses a risk of infection with blood-borne pathogens; and mitigation is possible with proper training, effective disposal strategies, and the use of safety devices. Adherence to these new recommendations should lead to more effective therapies, improved outcomes, and lower costs for patients with diabetes.
C orrect technique in insulin delivery is critical for optimal control of diabetes. This article reviews the most recent studies in the field and then offers new injection and infusion recommendations for insulin users. It is meant to complement and extend the injection recommendations published in 2010. 1 These latest recommendations were based on the results of the fourth Injection Technique Questionnaire (ITQ) survey (published elsewhere in this issue). From February 2014 through June 2015, 13,289 insulin-injecting patients with diabetes from 42 countries participated in the ITQ survey, one of the largest multinational studies of its kind. A smaller Infusion Technique Questionnaire survey was undertaken concurrently with the ITQ in 356 patients using continuous subcutaneous insulin infusion (CSII) in four countries and informed the drafting of the new infusion recommendations.
The ITQ survey results (for injection and infusion) and the initial draft of these recommendations were presented at the Forum for Injection Technique and Therapy: Expert Recommendations (FITTER) workshop held in Rome, Italy, on October 23 and 24, 2015, at which 183 physicians, nurses, educators, and allied health care professionals (HCPs) from 54 countries (see the list in Supplemental Appendix 1, available online at http://www. mayoclinicproceedings.org) 2 met to debate, revise, and adapt these proposals. FITTER was the fourth in a series of expert workshops that have issued recommendations on insulin delivery. 1, [3] [4] [5] MATERIALS AND METHODS Publications were identified using Medline, EMBASE, PubMed, and Cochrane Controlled Trials. The search was focused on the period between January 2008 and December 2015, although we had at our disposal the medical literature going back to 1980. We used the terms subcutaneous injections, insulin, injection technique, insulin infusion, CSII sets, infusion sets, and glucagon-like peptide-1 receptor agonists (GLP-1). For those seeking other related terms, a glossary is also available as Supplemental Appendix 2 (available online at http:// www.mayoclinicproceedings.org).
2 Of 368 articles found, 254 met the criteria for inclusion as outlined in the Cochrane Handbook for Systematic Reviews of Interventions. 6 One of us (K.W.S.) drafted the initial version of the recommendations. This draft was then extensively revised during 12 monthly web conferences with a group of international experts in injection and infusion techniques (see authors). This new draft was then extensively revised by the 183 expert invitees to the FITTER meeting in Rome. After FITTER, additional revisions were made by FITTER attendees. The current version reflects the collective input of these diabetes experts from around the world and bears little resemblance to the earlier drafts.
The panel used a previously established scale 1, 4, 7 for the strength of each recommendation: A ¼ strongly recommended, B ¼ recommended, and C ¼ unresolved issue. For grading the degree of scientific support for each recommendation, we used the following scale: 1 ¼ at least 1 rigorously performed study that is peer reviewed and published (excludes observational studies); 2 ¼ at least 1 observational, epidemiologic, or population-based published study; and 3 ¼ expert consensus opinion informed by broad patient experience.
This simplified version of the grading scales commonly used 7 was believed to be more appropriate for our field, where randomized, controlled outcome trials are rarely available but good-quality studies on the performance of devices do exist. Each recommendation is followed by a letter and number in bold (eg, A2). The letter indicates the importance that the recommendation should have in practice, and the number indicates its level of evidence in the medical literature. The most relevant publications bearing on a recommendation are also cited or summarized. Although these recommendations will be suitable for most patients, individual exceptions may occur for which the guidelines should be adapted.
ANATOMY Skin Thickness
The skin is the first obstacle a needle must traverse when giving an injection or infusion. A variety of studies of adult skin at injection sites using various imaging techniques have all shown similar results: the skin varies in thickness from approximately 1.25 to 3.25 mm in 90% of individuals and averages approximately 2.0 to 2.5 mm. Studies have included both healthy volunteers and persons with diabetes, and their results are consistent across age groups, sexes, body mass indexes (BMIs), and geographic locations. Studies included four ethnic groups in the United States 8 ; Italian 9 and South African 10 children and adolescents with type 1 diabetes; and groups of Chinese, 11 Indian, 12 Filipino, 13 and Korean adults 14 (most with type 2 diabetes). Details of these studies are summarized in Supplemental Figure 1 8 and Supplemental Tables 1-4 (available online at http://www.mayoclinicproceedings.org).
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The skin is slightly less thick in children, but by puberty it increases to adult levels. However, these differences are small and are irrelevant for insulin injections and infusions. In both children and adults, even the shortest needles (4 mm) reliably traverse the skin and enter the subcutaneous (SC) fat.
SC Thickness
The distance from the surface of the skin to the muscle fascia (ie, the sum of skin and SC thickness) determines the potential for intramuscular (IM) injection. Compared with skin thickness, which is relatively constant, SC tissue thickness varies widely. Ultrasound measurements of skin and SC thickness at insulin injection sites in adult patients with diabetes have recently been published. 11, 13 See Supplemental Tables 1-4 9-15 for a summary of findings from the most important of these studies. Gibney et al 8 and Hirsch et al 15 (separate reports on the same study) measured SC fat depth at single locations in the thigh, arm, abdomen, and buttock. Studies by Ludescher et al 16 and Sim et al 14 (where 8-10 measurements were taken and averaged for each body site) largely confirmed the ultrasound study findings from a single site.
Several rules of thumb have emerged from these studies: SC fat thickness increases in direct proportion to BMI; women, on average, have an approximately 5-mm greater SC fat thickness than men at the same BMI; and truncal sites (abdomen and buttocks) have thicker SC fat layers than limbs (thighs and arms) in the same individual. The most important outcome of these studies is that they inform us about the risk of IM injections. Intramuscular deposition of insulin leads to unpredictable (largely faster) absorption of insulin and destabilization of the blood glucose level. Intramuscular injections occur more frequently with longer needles, in slimmer and younger patients, males, and in those who use limbs rather than truncal sites for insulin delivery.
Supplemental Tables 5-9 8,11,14,15 (available online at http://www.mayoclinicproceedings. org) provide estimates of the IM injection risk by site, needle length, and patient type. Different risk estimates in several studies reflect differing patient populations with a wide range of average BMIs.
Children aged 0 to 2 years have higher BMIs and more SC tissue than preschool children. Preschool children (2-6 years old) are usually at the thinnest point in their lives, and both sexes usually have very little SC tissue. School-age children (7-13 years old) slowly gain SC tissue, but there are few sex differences until puberty. During puberty, young women gain considerably more SC tissue than young men owing to hormonal influences. See Supplemental Tables 1-4 9-15 for a summary of findings from the most important pediatric studies. See Supplemental Table 10 9,10 (available online at http://www.mayoclinicproceedings.org) for estimates of IM risk in pediatric patients by site, needle length, and patient age.
PHYSIOLOGY

Risk of IM Injections
Insulin absorption rates from IM injections differ according to the activity of the muscle. Muscle can be resting (eg, abdominal muscles in a recumbent person), active (abdominal muscles in a standing person), or exercising (abdominal muscles in a person doing sit-ups). Intramuscularinjected insulin is absorbed differently in resting, active, and exercising muscle, with the rate increasing as one progresses through the 3 stages.
Human insulins and analogues have different absorption profiles when deposited into muscle. Intramuscular injections, especially into working muscle, can distort absorption and, thus, decouple maximum blood glucose levels from peak insulin activity. This can cause poor glycemic control, including excessive glycemic variability. Intramuscular injections can lead to frequent and unexplained hypoglycemia according to several studies. [17] [18] [19] Patients may be unaware that they are injecting IM. Several clinical pointers can give clues as to whether the injection is IM or SC. Intramuscular injections can lead to a greater risk of bleeding, bruising, and pain. The pain may be described as stinging, and it worsens if the relevant muscle is contracted with the needle in situ. If a patient releases the syringe with the needle still under the skin, it may continue to stand upright if it is IM (whereas it topples over in SC injections). 20 Unexplained glycemic variability and episodes of hypoglycemia may suggest IM injection. At special risk are children, thin persons, and persons using longer needles or following improper technique.
Needle Length
The needle lengths that were once recommended for SC injection (for adults, !8 mm; for children, !6 mm) are now known to be too long because they increase the risk of IM injections without evidence of improved glucose control. [21] [22] [23] Shorter needles are much safer and are better tolerated and less painful. Hirsch et al 24 compared a 4-mm pen needle with 5-and 8-mm needles in a large randomized controlled study. The 4-mm needle was shown to be safe and efficacious in adult patients of all sizes (ie, equivalent glucose control); skin leakage was equivalent and pain scores were improved with the 4-mm needle. Similar studies have been performed in various other groups, [25] [26] [27] including obese patients. 28 All earlier studies on needle length [29] [30] [31] [32] [33] [34] [35] [36] [37] have also shown similar glucose control (glycated hemoglobin, glycated albumin, or fructosamine) without increased leakage with the shorterlength needle. The shortest-length pen needle is 4 mm, but the shortest syringe needle today is 6 mm long (the syringe needle has to pass through the vial septum or stopper). Insulin pharmacokinetics/pharmacodynamics has been shown to be the same when injected into resting individuals using short and long needles. 27 have been shown to be appropriate for all injecting patients. Their obstruction, bending, and breakage rates are the same as for conventional-quality needles (extremely low) and offer flow and ease-of-use advantages. A3
Site Care
The recommended injection and infusion sites are the abdomen, thigh, buttock, and upper arm. [72] [73] [74] [75] [76] Suggested boundaries in these sites for insulin delivery are stated in the golden rules (see the Appendix).
Recommendations.
n Patients should inspect the site before injection. Injections should be given into clean sites, only using clean hands. [77] [78] [79] A2 n If the site is found to be unclean it should be disinfected. Disinfection is also required in institutional settings such as hospitals and nursing homes. If alcohol is used, it must be allowed to dry completely before the injection is given. 80 Several basic steps are important to follow with any pen injector, but few of these are known by (or taught to) patients. For example, it is important not to accidentally push the thumb button before the pen needle tip is inserted in the SC tissue. In fact, it is best not to touch the thumb button until the needle is completely inserted. Once the thumb button is pushed, patients should keep pressure on it until the needle is completely withdrawn from the body. If the button is released while the needle is still in the skin, body fluid and cells may be aspirated into the cartridge and contaminate it. 93 Another important step is to always push the button vertically (along the axis of the pen). Some patients, especially the frail or elderly, are unable to completely inject their total dose because they are pushing the button obliquely, eg, by pushing on its edge, generating excessive resistance along its glide path. 94, 95 Recommendations.
n Pens should be primed before injections to ensure free and unobstructed flow. Manufacturer's instructions should be followed. Priming entails seeing at least a drop of insulin at the tip of the needle. Once free flow is verified, the patient may dial the desired dose and inject. 96 Recommendations.
d Syringe users should ensure that their device is appropriate for the concentration of insulin they are using. A3 d When drawing up insulin from a vial, the user should first draw air into the syringe at a dose equal to (or slightly greater than) the dose of insulin to be given. This air is then injected into the vial to facilitate withdrawal of insulin. A3 d If air bubbles are found in the syringe, tap on the barrel to bring them to the surface. They may then be removed by pushing the plunger up. A3 d With syringes, unlike pens, the needle does not need to be left under the skin for a count of 10 after the plunger has been fully depressed. 105 Lifting a Skinfold Lifting a skinfold is required when the distance from the skin surface to the muscle is less than or equal to the needle length. Lifting a skinfold in the abdomen nearly doubles the skin-tomuscle distance. In the thigh, it is sometimes difficult to lift a skinfold, and the mean increase in skin-to-muscle distance may be only 20%. In thin patients, thigh skinfolds may actually decrease the distance to muscle fasciadthe exact opposite of what is desired.
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Lifting a skinfold is rarely needed in the buttocks because of the abundance of SC tissue there. When performed in the arm, skinfolds must be lifted by someone other than the patient.
Recommendations.
d A correct fold is made by lifting the skin with the thumb and index finger (possibly adding the middle finger). If the skin is lifted using the whole hand, muscle may be lifted as well as SC tissue, which can lead to IM injections. 123 
A3
d Skinfolds should be lifted gently and not squeezed so tightly as to cause blanching or pain. A3 d The optimal sequence when injecting into a skinfold is as follows: (1) gently lift a skinfold, (2) inject the insulin slowly at a 90
angle to the surface of the skinfold, (3) let the needle remain in the skin for a count of 10 after the plunger is depressed (when using a pen), (4) withdraw the needle from the skin at the same angle it was inserted, (5) release the skinfold, and (6) dispose of the used needle safely. A3
Cloudy Insulin Resuspension
Several studies have shown that cloudy insulins are often inadequately resuspended. 110, [124] [125] [126] [127] Crystals of insulin must be mechanically agitated so that they go back into solution before injection, but many patients do not know how to do this or do it inappropriately. Inadequate resuspension can lead to varying concentrations of insulin and unpredictable clinical responses. A summary of key studies on insulin resuspension can be found in Supplemental Appendix 4 (available online at http://www.mayoclinicproceedings. org).
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Recommendations. Of these, only insulin is in common use for CSII. Despite more than 90 years of use, insulin injections and infusions are often performed incorrectly, with adverse clinical consequences for patients and additional costs for payers. Often, even simple rules are not taught or followed. The HCP has a crucial role in the proper use of these therapies. Proper technique is essential to achieve optimal diabetes control, reduce variability, and achieve desired outcomes. 18, 85, 119, [135] [136] [137] [138] Often the most important determinant of patients' injection technique is the knowledge and commitment of their HCP.
Recommendations.
n Key tasks of the HCP include helping patients (and caregivers) overcome the psychological obstacles related to injecting or infusing, especially at the initiation of treatment, and then teaching them how to perform the procedure correctly. A2 n The HCP must understand the anatomy and physiology of insulin delivery sites so that IM injections/infusions, LH, leakage, and other complications are avoided. A2 n The HCP must understand the pharmacokinetics of the therapeutic agents and the absorption profiles of the various delivery sites. A2
Therapeutic Education
Decisions regarding insulin therapy should be made jointly by the HCP and the patient (and caregivers). 137, 138 Not all patients receive appropriate education about injections/ infusions, and not all essential topics are covered. [139] [140] [141] Education in a group setting may lead to better adherence and lower glycated hemoglobin values if the HCP has training as an educator. 142 A summary of studies on therapeutic education for insulin delivery can be found in Supplemental Appendix 5 (available online at http://www. mayoclinicproceedings.org). 143, 144 Recommendations. 151 An even rarer type of lipodystrophy is amyloidosis, [152] [153] [154] [155] for which a biopsy and pathologic diagnosis are usually necessary. Insulin injected into amyloid deposits may have substantially impaired absorption. Usually, LH regresses after stopping insulin injections into the lesions, whereas localized amyloidosis does not. Distinguishing these lesions is clinically important.
Lipohypertrophy is common, although studies vary on the exact frequency. A Spanish study 156 found LH in nearly two-thirds of injecting patients (64.4%) (type 1 diabetes, 72.3% vs type 2 diabetes, 53.4%). An Italian study 143 found the prevalence to be 48.7%, and in a Chinese study 157 it was 53.1%. The absorption of insulin injected into LH lesions may be erratic and unpredictable, which can lead to hyperglycemia, unexpected hypoglycemia, or increased glucose variability. 158, 159 Conversely, patients who switch from injecting into LH lesions to normal tissue are at risk for hypoglycemia unless they lower their doses. A summary of additional studies in LH and pointers for optimizing the physical examination for LH are presented in Supplemental Appendix 6 (available online at http://www. mayoclinicproceedings.org) (Irl B. Hirsch, MD, oral communication, October 24, 2015) . 88, [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] Lipoatrophy studies are also summarized at this site. Injection can be rotated from one body region to another (abdomen to thigh, to buttock, to arm), but note that absorption characteristics change depending on the type of insulin given. Analogues may be given at any injection site with similar uptake and action (pharmacokinetics/pharmacodynamics), but human insulins (regular, NPH) vary substantially, with absorption being fastest from the abdomen and slowest from the buttocks. 
Bleeding and Bruising
Needles will occasionally hit a blood vessel or a capillary bed, producing local bruising or bleeding. 194 Today's needles are of much smaller diameter than they once were, and the amount of blood loss is usually inconsequential. Applying pressure to the site for 5 to 10 seconds should stop the bleeding. Varying the needle length does not alter the frequency of bleeding or bruising.
Recommendations. 
Leakage of Insulin
There are 3 types of leakage. Leaking from the pen is due to a poor seal between the needle and the cartridge in the pen. Dripping from the needle (while it is on the pen) can occur when the plunger is not held down correctly or the needle is taken out of the skin too soon. Reflux or backflow out of the injection site can happen when the needle is taken out too soon or for some other reason (obese patient). Additional studies on leakage are summarized in Supplemental Appendix 9 (available online at http://www. mayoclinicproceedings.org). 195, 196 Data on innovations in needle geometry are available in Supplemental Appendix 10 (available online at http://www.mayoclinicproceedings.org). [197] [198] [199] Recommendations: Leakage at Cartridge and Pen Needle Connection. d Count to 10 after the plunger is fully depressed before removing the needle from the skin to allow time for expulsive forces to be transmitted through all pen parts to the insulin column in the cartridge. A2 d By trial and error, patients may learn how long they need to hold the button down and the needle under the skin to avoid dripping from the needle tip or backflow out of the skin. This may be less than 10 seconds. A2 d Larger doses may be split to reduce the volume of insulin. A2
Recommendations: Skin Leakage. PSYCHOLOGY Beginning insulin therapy can be fraught with psychological hurdles, regardless of the age of the patient. Foremost among these is the fear of pain. Insulin injections are usually not painful, except in the event that the needle hits a nerve ending, which is quite infrequent. Nevertheless, some patients are quite sensitive to sensations described as painful. Patient awareness of injection discomfort has been studied extensively and is related to 3 key factors: needle length, needle diameter, and injection context. Injection context includes the environment (eg, noise and the presence of other people), the appearance of the needle, and the anxieties of the HCP and the family. The more apprehension the latter display, the greater the pain and anxiety felt by the patient. 202, 203 This reverse transference places a large responsibility on caregivers to assess their own attitudes toward injection pain. Some patients note discomfort when injecting insulins that have a low pH. This seems, anecdotally, to be reported more commonly in children. Other studies on the psychology of insulin delivery are summarized in Supplemental Appendix 11 (available online at http://www.mayoclinicproceedings. org).
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Recommendations Emotional and Psychosocial Issues. but not jabbing movement. Pain fibers are in the skin, and going through the skin too slowly or too forcefully may increase the pain. A1 d Inject the insulin slowly, ensuring that the plunger (on the syringe) or thumb button (on the pen) has been fully depressed and all the insulin has been injected. With pens, the patient should count to 10 after the button has been depressed before withdrawing the needle to get the complete dose. A3 d The HCP should teach the importance of rotation and create a rotation pattern with the patient when initiating injection therapy. The message should be: "Insulin will not be well-absorbed if it is always injected into the same area. It is important to move injections at least half an inch (1 cm) away from the previous injection and to use all injection sites on the body (back of the arms, buttocks, thighs, and abdomen Insulin Infusion Sets for CSII Continuous SC insulin infusion using an insulin pump has been a treatment modality for patients with diabetes, primarily those with type 1, for more than 30 years. 235 Insulin infusion sets (IISs) are required to deliver insulin into the SC tissue, but their role in CSII therapy is often underappreciated by HCPs. As a result, advances in IIS technology are stagnant and overshadowed by the innovative advances of insulin infusion pumps. There are, nevertheless, a large variety of IIS options available. Complications related to IISs are common and include infusion site, technical, and metabolic manifestations; for these reasons, IISs are considered the Achilles heel of CSII. 236 In a randomized, open-label, pharmacokinetic study by McVey et al, 237 irregularities in insulin delivery during CSII were observed when in-line pressure was used as an indicator for flow. Significant increases in pressure during infusion (which suggests flow interruptions) were found over a 24-hour period in 20 adults with type 1 diabetes, often without triggering the pump's occlusion alarm. The authors concluded that these silent, or subalarm, occlusions may potentially contribute to unexplained hyperglycemia in patients receiving CSII.
Hirsch 238 reported the occurrence of silent occlusions using insulin diluent in healthy volunteers, in whom pressure measurements were made. Silent occlusion was defined as a continuous rise in pressure of at least 30 minutes without triggering the pump occlusion alarm. These pressure-rise events occur frequently during SC infusion (>35% of infusions). Furthermore, these studies evaluated the efficacy of a catheter with an additional lumen on its side (known as a side-ported catheter) for reducing flow interruptions or silent occlusions. The use of a side-ported set lowered the incidence of silent occlusions by more than 75% compared with a conventional Teflon IIS. 239 Similar criteria for choosing needle length for pen needles should apply to choosing optimal IIS cannula length. Skin thickness studies suggest that short cannula lengths are appropriate to help reduce the risk of IM insertion. Bolick 240 conducted corollary imaging studies using both fluoroscopy (in swine) and magnetic resonance imaging (in human volunteers) to characterize the IIS performance during infusion and bolusing. The studies provide visual evidence that IIS cannulas measuring 9 mm or longer may increase the risk of IM insertion, particularly in body areas of reduced adipose tissue, such as the back of the arm and the thigh. A summary of other studies on the delivery issues surrounding CSII is presented in Supplemental Appendix 13 (available online at http://www.mayoclinic proceedings.org). 161, [241] [242] [243] [244] Recommendations.
d Population studies suggest that CSII cannulas should be changed every 48 to 72 hours with the goal of minimizing infusion site adverse events and potential metabolic deterioration. However, these times are patient dependent and should be adjusted accordingly. 
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Recommendations.
d Safety-engineered devices play a critical role in protecting injectors, pump users, and downstream workers. Nurses and other HCPs at risk must receive appropriate education and training in how to minimize risk by following optimal techniques, using safety devices, and wearing appropriate protective clothing (eg, gloves). A1 d Safety injection devices should be considered first-line choice if injections are given by a third party. Pens and syringes with needles used in this setting should have protective mechanisms for all sharp ends of the delivery device. A2 d The HCPs should be involved in the trialing and choice of devices to be used in their health care setting. Evaluation before adoption should include key specialists (eg, infection control, occupational health, and experienced end users). 273 Similar initiatives in other countries (eg, Turkey, Belgium, Italy, Germany, and China) do not carry the FIT name but have led to similar guidelines. [280] [281] [282] [283] [284] [285] These country initiatives play a critical role in establishing best practice and in changing behavior for countless patients and HCPs worldwide. Such guidelines should be updated regularly. Some countries (eg, Canada and the United Kingdom) now publish their guidelines only online to have more flexibility when updating, increase ease of access, and save on resources.
In these new recommendations we added a variety of themes (eg, infusion, safety) and covered all the key studies published since TITAN. However, a variety of key injecting parameters have not been studied in sufficient depth and in specific populations for recommendations to be made. These parameters include injections during pregnancy, injections using the newer analogues or GLP-1 receptor agonists, and injections in special populations (eg, babies and the very elderly) or under special conditions (eg, SC edema). Investigators are encouraged to address these issues through prospective, randomized clinical trials.
CONCLUSION
These evidence-based recommendations provide a new, practical, and comprehensive set of guidelines for patients and professionals worldwide. If followed, they should ensure safe and efficacious delivery of diabetic therapies into the SC space. To assist with implementation of these new recommendations, we provide 6 sets of golden rules in the Appendix. These rules are meant as a clear and simple road map for nurses, educators, and patients. If the rules are followed, nearly all of the new recommendations will be implemented. 
APPENDIX. SIX SETS OF GOLDEN RULES
